Anacor Pharmaceuticals Co-Founder Lucy Shapiro Awarded National Medal of Science

  Anacor Pharmaceuticals Co-Founder Lucy Shapiro Awarded National Medal of

Business Wire

PALO ALTO, Calif. -- January 17, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that its co-founder and
board member, Dr. Lucy Shapiro was named as a recipient of the National Medal
of Science, one of the highest honors bestowed by the United States Government
upon scientists, engineers, and inventors.

The National Medal of Science was created by statute in 1959 and is
administered for the White House by the National Science Foundation. Awarded
annually, the Medal recognizes individuals who have made outstanding
contributions to science and engineering. A committee of Presidential
appointees selects nominees on the basis of their extraordinary knowledge in
and contributions to chemistry, engineering, computing, mathematics, or the
biological, behavioral/social, and physical sciences.

“Anacor congratulates Lucy on this tremendous achievement,” said David Perry,
Anacor’s Chief Executive Officer. “Lucy’s groundbreaking research contributed
to the creation of Anacor’s technology platform which has resulted in eight
drug candidates that are currently in development.”

Lucy Shapiro, Ph.D., is the Virginia and D.K. Ludwig Professor of Cancer
Research and Director of the Beckman Center in the School of Medicine at
Stanford University. Dr. Shapiro is a Fellow of the American Association for
the Advancement of Sciences and has been elected to the National Academy of
Sciences, the American Academy of Microbiology, the American Academy of Arts
and Sciences and the Institute of Medicine of the National Academy of Sciences
for her work in the fields of molecular biology and microbiology. She was
elected to the American Philosophical Society and received the Selman Waksman
Award from the National Academy of Sciences in 2005. She was a non-executive
director of GlaxoSmithKline from 2001 to 2006 and is on the board of
Gen-Probe, Inc. and Pacific Biosciences of California, Inc. She received a
B.S. from Brooklyn College and a Ph.D. in molecular biology from the Albert
Einstein School of Medicine.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, a topical antifungal for the treatment of
onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365 (formerly known as GSK2251052, or GSK‘052),
a systemic antibiotic for the treatment of infections caused by Gram-negative
bacteria, which previously was licensed to GlaxoSmithKlineLLC, or GSK. GSK
will be returning all rights to the compound to us and we are considering our
options for further development, if any, of this compound. We have discovered
three other compounds that we have out-licensed for further development — two
compounds for the treatment of animal health indications that are licensed to
Eli Lilly and Company and AN5568, also referred to as SCYX-7158, for human
African trypanosomiasis (HAT, or sleeping sickness), which is licensed to
Drugs for Neglected Diseases initiative, or DNDi. We also have a pipeline of
other internally discovered topical and systemic boron-based compounds in
development. For more information, visit


Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Director, Investor Relations and Corporate Communications
Press spacebar to pause and continue. Press esc to stop.